Clinical trials
Lung Cancer (Diagnosis) clinical trials
Below are recruiting lung cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 774 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06457906RecruitingPhase 3
Focused radiation vs whole brain radiation for up to 10 lung cancer brain spots
This trial compares two types of radiation for people with small cell lung cancer that has spread to the brain (10 or fewer spots). One approach uses focused radiation only on the tumors, the other treats the whole brain while trying to protect memory. The goal is to see which works better with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06974981Recruiting
Using lung cancer screening to find and treat COPD
This study looks at how lung cancer screening can also help find and manage COPD, a lung condition that often goes undetected. If you are a current or former smoker and meet certain age and smoking history criteria, you may join to help improve screening and care for both lung cancer and COPD.
Philadelphia, PennsylvaniaAges 50–80 - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT07739758RecruitingPhase 3
Study of two drugs for newly diagnosed extensive-stage small cell lung cancer
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT05317858RecruitingPhase 3
Open the brain’s blood barrier to treat lung cancer brain spots
This trial tests whether using focused ultrasound to temporarily open the brain’s blood barrier—plus standard immune therapy—can better treat non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to help medicines reach the brain tumor spots more effectively, while still using the usual lung cancer treatment.
Phoenix, ArizonaAges 18–100 - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
Birmingham, AlabamaAges 18 years+ - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
La Jolla, CaliforniaAges 45–80 - NCT06616766RecruitingPhase 1/Phase 2
Study of YH42946 for advanced cancer with HER2 or EGFR changes
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Fairfax, VirginiaAges 18 years+ - NCT07431827RecruitingPhase 3
Study of pembrolizumab plus calderasib for KRAS G12C lung cancer after surgery
This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.
Ciudad Autónoma de Buenos Aires, Buenos AiresAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT07111936Recruiting
Using CONNECT to help multilingual smokers get lung cancer screening
This study tests a program called CONNECT to help current smokers aged 50-80 get lung cancer screening. It aims to see if the program works well for people who speak different languages.
San Francisco, CaliforniaAges 50–80 - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT05627674Enrolling by invitation
Help improve lung cancer screening and quitting support uptake
This study tests a “precision” approach to help people who are newly eligible for lung cancer screening actually get screened and start smoking-cessation treatment. If it works, it could make screening and quitting help easier to access and more engaging.
St Louis, MissouriAges 18 years+ - NCT05236946RecruitingPhase 3
Brain radiation timing study for gene-mutated lung cancer
This study compares giving brain radiation right away versus waiting, in people with lung cancer that has an EGFR or ALK gene change and has spread to the brain but causes no symptoms. It aims to see which approach helps control the brain cancer better and keeps quality of life stable.
Mumbai, MaharashtraAges 18–99 - NCT04216121Recruiting
Testing a focused radiation approach for limited cancer spread
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
LeuvenAges 18 years+ - NCT05623319RecruitingPhase 2
Pembrolizumab plus olaparib for extensive small cell lung cancer
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
Meldola, Forlì CesenaAges 18 years+ - NCT07039656RecruitingPhase 2
Toripalimab plus chemo after NSCLC surgery
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Guangzhou, GuangdongAges 18–75 - NCT06739928RecruitingPhase 2
Irinotecan liposome with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
Guangzhou, GuangzhouAges 18–70 - NCT07188480Recruiting
DNA and RNA testing for advanced lung cancer
This study tests a new way to analyze DNA and RNA from lung tumor samples taken during a bronchoscopy. It aims to find genetic changes that could help guide treatment for people with advanced non-small cell lung cancer.
Bologna, BolognaAges 18 years+ - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+
Hear when a new Lung Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (diagnosis)?
- Yes. Clin2 currently lists 774 recruiting lung cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.